Metformin: a review of its pharmacological properties and therapeutic use
- PMID: 387488
Metformin: a review of its pharmacological properties and therapeutic use
Abstract
In a survey, the pharmacological and clinical documentation of metformin is presented and discussed, and the present state of knowledge relating to metformin-associated lactic acidosis is reviewed. The use of metformin in the treatment of diabetes is based on clinical experience over twenty years. It has been well documented that metformin is effective in maturity-onset diabetes both as monotherapy and in combination with a sulphonylurea. An advantage of metformin treatment is the tendency to weight reduction and the absence of significant hypoglycaemia; blood glucose levels are reduced only to normal. The disadvantages are the gastro-intestinal side effects and the potential risk of vitamin B 12 and folic acid deficiency during long-term use. Metformin-associated lactic acidosis is a very rare complication, which has mainly occured in patients with serious renal insufficiency or other contra-indications to the use of metformin. The association between phenformin and lactic acidosis has led to withdrawal of this biguanide in several countries. Metformin differs from phenformin in certain important respects, and the normal use of metformin does not involve the risk of side effects disproportionate to the intended effect. Further experimental studies are required to substantiate pharmacokinetics and metabolic effects of metformin in man.
Similar articles
-
Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.Drugs. 1995 May;49(5):721-49. doi: 10.2165/00003495-199549050-00007. Drugs. 1995. PMID: 7601013 Review.
-
[Biguanides: reasons for withdrawal of drugs and remaining indications].Acta Med Austriaca. 1978;5(3):85-8. Acta Med Austriaca. 1978. PMID: 752219 German.
-
Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.J Fam Pract. 1996 Jun;42(6):612-8. J Fam Pract. 1996. PMID: 8656173 Review.
-
Metformin in noninsulin-dependent diabetes mellitus.Pharmacotherapy. 1996 May-Jun;16(3):327-51. Pharmacotherapy. 1996. PMID: 8726592 Review.
-
A risk-benefit assessment of metformin in type 2 diabetes mellitus.Drug Saf. 1999 Jun;20(6):489-503. doi: 10.2165/00002018-199920060-00003. Drug Saf. 1999. PMID: 10392666 Review.
Cited by
-
Ianus Bifrons: The Two Faces of Metformin.Cancers (Basel). 2024 Mar 26;16(7):1287. doi: 10.3390/cancers16071287. Cancers (Basel). 2024. PMID: 38610965 Free PMC article. Review.
-
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.Trials. 2024 Feb 3;25(1):103. doi: 10.1186/s13063-024-07929-w. Trials. 2024. PMID: 38308321 Free PMC article.
-
Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults.Front Aging. 2023 Oct 11;4:1272336. doi: 10.3389/fragi.2023.1272336. eCollection 2023. Front Aging. 2023. PMID: 37886013 Free PMC article. Review.
-
Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials.BMC Med. 2022 Oct 24;20(1):402. doi: 10.1186/s12916-022-02599-4. BMC Med. 2022. PMID: 36280839 Free PMC article.
-
Transdermal Delivery of Metformin Utilizing Ionic Liquid Technology: Insight Into the Relationship Between Counterion Structures and Properties.Pharm Res. 2022 Oct;39(10):2459-2474. doi: 10.1007/s11095-022-03394-9. Epub 2022 Sep 28. Pharm Res. 2022. PMID: 36171345